Bruker Corporation’s introduction of the Beacon Discovery™ Optofluidic System marks a significant advancement for contract research organizations (CROs) and service laboratories. Launched at AACR 2025, this benchtop platform makes live single-cell functional analysis more affordable and operationally efficient, enabling labs to offer cutting-edge services to clients in immuno-oncology, infectious diseases, and regenerative medicine.
Beacon Discovery builds on Bruker’s proven Opto-Electrical Positioning (OEP) and OptoSelect™ technologies, offering precise single-cell control, longitudinal multi-parameter assays, and full cell recovery for downstream molecular analysis. Its intuitive design and flexible workflows allow contract labs to quickly adapt to client-specific needs, improving turnaround times and delivering superior data quality.
Beacon Discovery provides lower running costs and pre-order availability, making it poised to become a cornerstone for CROs aiming to stay competitive in the growing single-cell analysis market.
Benefits of Beacon Discovery for Contract Testing Laboratories:
- Opens new revenue streams with single-cell functional and genomic analysis services
- Accelerates project timelines with integrated live-cell imaging and sequential assays
- Customizable workflows cater to diverse client research requirements
- Reduces equipment overhead with scalable, benchtop design
- Enhances client satisfaction with high-precision, reproducible results
- Access to Bruker’s Technology Access Program (TAP) for early evaluation
Bruker anticipates commercial shipments of the Beacon Discovery later in 2025. Now accepting pre-orders for labs seeking an early advantage.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. The original press release was provided by Bruker.